Navigation Links
Second Quarter Health Care M&A Strongest In Years According To New Report From Irving Levin Associates, Inc.
Date:7/9/2008

2,817,300,000 3 %

Technology subtotal $80,688,917,000 94 %

Total health care $85,495,925,000 100 %

*Preliminary figures

The health care technology segment attracted the largest amount of capital, capturing nearly 95 cents out of every dollar invested in health care M&A. This portion is up from the first quarter when 80 cents out of every health care M&A dollar was spent in the technology sectors.

The number of deals announced in each sector of the health care industry appears in the chart below, along with comparisons to the prior quarter (Q1:08) and the year-ago quarter (Q2:07).

The Health Care M&A Market Q2:08 - Deal Volume By Sector

Q2:08 Q1:08 % Q2:07 %

Sector Deals* Deals Change Deals Change

Services Segment:

Long-Term Care 21 28 -25% 27 -22%

Physician Groups 12 12 0% 6 100%

Home Health Care 13 11 18% 18 -28%

Hospitals 12 10 20% 15 -20%

Labs, MRI, Dialysis 8 10 -20% 12 -33%

Managed Care 3 7 -57% 9 -67%

Rehabilitation 4 6 -33% 4 0%

Behavioral Health

Care 3 3 0% 3 0%

Other 34 23 48% 27 26%

Services Subtotal 110 110 0% 121 -9%

Technology Segment:

Medical Devices 51 35 46% 40 28%

Pharmaceuticals 38 34 12% 39 -3%

Biotechnology 46 29 59% 37 24%

e-Health
'/>"/>

SOURCE Irving Levin Associates, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Dynavax Issued Landmark Patent Covering Second-Generation TLR9 Agonists
2. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
3. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
6. Carrington Reports Second Quarter 2007 Results
7. Response Genetics Reports Second Quarter 2007 Financial Results
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Transgenomic, Inc. Reports Second Quarter 2007 Results
10. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
11. GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 2National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 3National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 4Rodent smoke screen 2Superior offspring without genetic modification 2Eastern Europes First Novalis Tx 28TM 29 Radiosurgery Platform Begins Radiotherapy Treatments in Latvia using RapidArc 28R 29 Technology 5467 1Eastern Europes First Novalis Tx 28TM 29 Radiosurgery Platform Begins Radiotherapy Treatments in Latvia using RapidArc 28R 29 Technology 5467 2Eastern Europes First Novalis Tx 28TM 29 Radiosurgery Platform Begins Radiotherapy Treatments in Latvia using RapidArc 28R 29 Technology 5467 3National Intrepid Center of Excellence To Combat Traumatic Brain Injury With Sophisticated Brain Mapping Technology From Elekta 5462 1National Intrepid Center of Excellence To Combat Traumatic Brain Injury With Sophisticated Brain Mapping Technology From Elekta 5462 2National Intrepid Center of Excellence To Combat Traumatic Brain Injury With Sophisticated Brain Mapping Technology From Elekta 5462 3ZyStor Therapeutics Inc Cleared to Begin Clinical Trial for Targeted Protein Therapeutic for the Treatment of Pompe Disease 5457 1ZyStor Therapeutics Inc Cleared to Begin Clinical Trial for Targeted Protein Therapeutic for the Treatment of Pompe Disease 5457 2ZyStor Therapeutics Inc Cleared to Begin Clinical Trial for Targeted Protein Therapeutic for the Treatment of Pompe Disease 5457 3